- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04253873
Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas
Study Overview
Detailed Description
Temozolomide combined with concurrent radiotherapy, followed by 6 cycles of temozolomide adjuvant chemotherapy, can prolong the patient's survival, and the 2-year survival rate has increased from 10.4% to 26.5%. Great progress has been made, but the prognosis for glioma patients remains poor. For patients with poor-quality high-grade gliomas, more effective new treatments are urgently needed to achieve the purpose of survival benefit.
Targeting VEGFs to inhibit tumor angiogenesis has shown good efficacy in a variety of tumors including colon cancer, gastric cancer, lung cancer, liver cancer and breast cancer. However, for gliomas, anti-tumor angiogenesis drugs can improve patient OS Evidence related to PFS is still scarce. Compared with other targeted drugs with multiple kinase targets, apatinib has not only an advantage in price but also less side effects. Therefore, based on relevant data from previous studies, a basic and clinical study of this apatinib combined with temozolomide for high-grade gliomas was performed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hui Wu, archiater
- Phone Number: 13503716710
- Email: wuhui7008@126.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
Contact:
- hui Wu
- Phone Number: 13503716710
- Email: wuhui7008@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Age: 18 ~ 70 years old, male or female; 2. ECOG score: 0-2 points; 3. Expected survival time ≥ 3 months; 4. Patients diagnosed with high-grade (WHO III, IV) gliomas by pathology, and patients whose disease recurrence is judged by contrast imaging, have at least one measurable lesion on the skull magnetic resonance; 5. Patients who have not been controlled or relapsed after previous first-line standard treatment; 6. The main organs function normally, that is, they meet the following standards:
The blood routine examination standards must be met (no blood transfusion and blood products within 14 days, no correction using G-CSF and other hematopoietic stimulating factors)
- HB≥90 g / L;
- ANC≥1.5 × 109 / L;
- PLT≥80 × 109 / L;
Biochemical inspection must meet the following standards:
- TBIL <1.5ULN;
- ALT and AST <2.5ULN, but <5ULN for patients with liver metastases;
- Serum Cr≤1.25ULN or endogenous creatinine clearance rate> 45 ml / min (Cockcroft-Gault formula); 7. Women of childbearing age must have taken reliable contraceptive measures or performed a pregnancy test (serum or urine) within 7 days before enrollment, with negative results, and be willing to use appropriate methods during the test and 8 weeks after the last dose contraception. For men, consent must be given to appropriate contraception or surgical sterilization during the trial and 8 weeks after the last test drug administration; 8. Participants voluntarily joined the study and signed informed consent, with good compliance and cooperation with follow-up.
Exclusion Criteria:
- 1. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction; 2. Patients with urinary protein positive (urinary protein detection 2+ or more, or 24-hour urine protein quantification> 1.0g); 3. Patients with hypertension who cannot be reduced to normal range with antihypertensive medication (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg) 4. Concurrent active cancer that requires non-surgical treatment (eg chemotherapy, radiotherapy, adjuvant therapy) 5. Previously suffered severe cardiovascular disease: myocardial ischemia or myocardial infarction of grade Ⅱ or above, poorly controlled arrhythmia (including QTc interval ≥450 ms for men, ≥470 ms for women); according to NYHA standards, grade Ⅲ ~ Ⅳ Cardiac insufficiency, or color Doppler ultrasound examination of the left ventricular ejection fraction (LVEF) <50%; 6. For previous symptoms of cerebral hemorrhage of grade 2 or higher, bleeding in other parts of grade ≥CTCAE grade 3 occurred within 4 weeks before the first use of the study drug; 7. Abnormal blood coagulation function (International Normalized Ratio of Prothrombin Time (INR)> 1.5 ULN or Prothrombin Time (PT)> ULN + 4 seconds or APTT> 1.5 ULN), with bleeding tendency 8. Patients who are receiving thrombolytic or anticoagulant therapy and treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; small-dose prophylaxis is allowed for preventive purposes provided that INR is ≤1.5 Warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg and 100mg daily); 9. Arterial / venous thrombosis events, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurring within 6 months before the first medication; 10. Severe or non-healing wounds, ulcers or fractures or abdominal fistulas, gastrointestinal perforations, abdominal abscesses, major medical history of open biopsy or significant trauma within 28 days prior to administration except for craniotomy and tumor removal 11. The researcher judges other situations that may affect the progress of the clinical study and the determination of the research results, and considers them unsuitable for inclusion.
12. Pregnant or lactating women; 13. Have previously used other anti-angiogenic drugs or preparations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib mesylate + temozolomide
Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
|
Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-month PFS rate
Time Frame: up to 1 year
|
Proportion of progression-free survival up to 6 months
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: up to 1 year
|
Refers to the date from the random date to the first occurrence of disease progression or death from any cause, whichever occurs first.
|
up to 1 year
|
Overall survival (OS)
Time Frame: up to 1 year
|
Means from random date to the date of death for any reason
|
up to 1 year
|
Objective response rate (ORR)
Time Frame: up to 1 year
|
Refers to the proportion of patients whose tumors have shrunk to a certain level and maintained for a certain period of time, including cases of CR and PR.
The solid tumor remission assessment standard (RECIST 1.1) was used to evaluate the objective tumor remission.
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hui Wu, archiater, Henan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Protein Kinase Inhibitors
- Temozolomide
- Apatinib
Other Study ID Numbers
- AHEAD-AHN02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-grade Gliomas
-
National Cancer Institute (NCI)CompletedRecurrent High-Grade Gliomas | Malignant Gliomas | Progressive Low-Grade GliomasUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Boston Children's HospitalDana-Farber Cancer Institute; National Institute for Biomedical Imaging and...Recruiting
-
Beth Israel Deaconess Medical CenterCompleted
-
National Cancer Institute (NCI)CompletedRecurrent High-Grade Gliomas | Malignant GliomasUnited States
-
Huashan HospitalCompleted
-
Lee's Pharmaceutical LimitedUnknown
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.RecruitingWHO Grade III Gliomas | WHO Grade IV GliomasChina
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedRefractory Low-grade Gliomas | Recurrent Low-grade GliomasAustria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
-
National Cancer Institute (NCI)Terminated
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Huazhong University of Science and TechnologyUnknown
-
Ruijin HospitalActive, not recruitingGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaChina